Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

Jul 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-07-21

Reporting Person: Francois Cedric (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-21	Common Stock	M	14410	$4.31	Acquired	1234243	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-21	Stock Option (Right to Buy)	$4.31	M	14410	Disposed	2027-08-20	Common Stock (14410)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	234411	Indirect

Footnotes

F1: The securities are held by The Francois-DuBois Educational Trust (the "Trust"), for which the Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.

F2: This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.